Sex specific effects of irisin on the skeleton

Abstract

Irisin, the circulating protein derived from cleavage of fibronectin type III domain containing protein 5 (FNDC5) has attracted considerable attention regarding its positive effects on a number of organs/tissues such as fat, brain, and heart. However, effects on bone can appear to be either positive or negative depending on context and sex. Sex differences have also been described in Alzheimer’s disease also emphasizing sex differences in response to irisin. Here in this review, we outline and focus on the effects of irisin on osteoblasts, osteoclasts, and osteocytes, murine models, and human studies. The consideration of sex effects is necessary especially in the context of irisin serving as a therapeutic.

References

[1] Boström P, et al.. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature, 2012, 481: 463-468.

[2] Liu, J., Qi, B., Gan, L., Shen, Y. & Zou, Y. A bibliometric analysis of the literature on irisin from 2012-2021. Int. J. Environ. Res. Public Health19, 6153 (2022).

[3] Teufel A, Malik N, Mukhopadhyay M, Westphal H. Frcp1 and Frcp2, two novel fibronectin type III repeat containing genes. Gene, 2002, 297: 79-83.

[4] Ferrer-Martínez A, Ruiz-Lozano P, Chien KR. Mouse PeP: a novel peroxisomal protein linked to myoblast differentiation and development. Dev. Dyn., 2002, 224: 154-167.

[5] Yu Q, et al.. FNDC5/Irisin inhibits pathological cardiac hypertrophy. Clin. Sci., 2019, 133: 611-627.

[6] Chi C, et al.. Exerkine fibronectin type-III domain-containing protein 5/irisin-enriched extracellular vesicles delay vascular ageing by increasing SIRT6 stability. Eur. Heart J., 2022, 43: 4579-4595.

[7] Shi H, et al.. Exercise-inducible circulating extracellular vesicle irisin promotes browning and the thermogenic program in white adipose tissue. Acta Physiol., 2024, 240. ArticleID: e14103

[8] Sánchez B, Muñoz-Pinto MF, Cano M. Irisin enhances longevity by boosting SIRT1, AMPK, autophagy and telomerase. Expert Rev. Mol. Med., 2022, 25. ArticleID: e4

[9] Wrann CD, et al.. Exercise induces hippocampal BDNF through a PGC-1α/FNDC5 pathway. Cell Metab., 2013, 18: 649-659.

[10] Xiong XQ, et al.. FNDC5 attenuates adipose tissue inflammation and insulin resistance via AMPK-mediated macrophage polarization in obesity. Metabolism, 2018, 83: 31-41.

[11] Young MF, Valaris S, Wrann CD. A role for FNDC5/Irisin in the beneficial effects of exercise on the brain and in neurodegenerative diseases. Prog. Cardiovasc. Dis., 2019, 62: 172-178.

[12] Islam MR, et al.. Exercise hormone irisin is a critical regulator of cognitive function. Nat. Metab., 2021, 3: 1058-1070.

[13] Liu TY, et al.. Irisin inhibits hepatic gluconeogenesis and increases glycogen synthesis via the PI3K/Akt pathway in type 2 diabetic mice and hepatocytes. Clin. Sci., 2015, 129: 839-850.

[14] Xin C, et al.. Irisin improves fatty acid oxidation and glucose utilization in type 2 diabetes by regulating the AMPK signaling pathway. Int. J. Obes., 2016, 40: 443-451.

[15] Wang H, et al.. Irisin plays a pivotal role to protect the heart against ischemia and reperfusion injury. J. Cell Physiol., 2017, 232: 3775-3785.

[16] Kim H, et al.. Irisin mediates effects on bone and fat via αV integrin receptors. Cell, 2018, 175: 1756-1768.e1717.

[17] Bao JF, She QY, Hu PP, Jia N, Li A. Irisin, a fascinating field in our times. Trends Endocrinol. Metab., 2022, 33: 601-613.

[18] Aydin S, et al.. A comprehensive immunohistochemical examination of the distribution of the fat-burning protein irisin in biological tissues. Peptides, 2014, 61: 130-136.

[19] Lv J, et al.. Study on the distribution and elimination of the new hormone irisin in vivo: new discoveries regarding irisin. Horm. Metab. Res., 2015, 47: 591-595.

[20] Korta P, Pocheć E, Mazur-Biały A. Irisin as a multifunctional protein: implications for health and certain diseases. Medicina, 2019, 55: 485.

[21] Shimonty A, et al.. Deletion of FNDC5/irisin modifies murine osteocyte function in a sex-specific manner. Elife, 2024, 12: RP92263.

[22] Hu X, et al.. Irisin as an agent for protecting against osteoporosis: A review of the current mechanisms and pathways. J. Adv. Res, 2024, 62: 175-186.

[23] Maak S, Norheim F, Drevon CA, Erickson HP. Progress and challenges in the biology of FNDC5 and irisin. Endocr. Rev., 2021, 42: 436-456.

[24] Lourenco MV, et al.. Exercise-linked FNDC5/irisin rescues synaptic plasticity and memory defects in Alzheimer’s models. Nat. Med., 2019, 25: 165-175.

[25] Wang K, et al.. Irisin exerts neuroprotective effects on cultured neurons by regulating astrocytes. Mediat. Inflamm., 2018, 2018. ArticleID: 9070341

[26] Peng J, et al.. Irisin protects against neuronal injury induced by oxygen-glucose deprivation in part depends on the inhibition of ROS-NLRP3 inflammatory signaling pathway. Mol. Immunol., 2017, 91: 185-194.

[27] Zhao YT, et al.. Irisin promotes cardiac progenitor cell-induced myocardial repair and functional improvement in infarcted heart. J. Cell Physiol., 2019, 234: 1671-1681.

[28] Liao Q, et al.. Irisin exerts a therapeutic effect against myocardial infarction via promoting angiogenesis. Acta Pharm. Sin., 2019, 40: 1314-1321.

[29] Xiong X, et al.. Irisin attenuates sepsis-induced cardiac dysfunction by attenuating inflammation-induced pyroptosis through a mitochondrial ubiquitin ligase-dependent mechanism. Biomed. Pharmacother., 2022, 152. ArticleID: 113199

[30] Askari H, et al.. A glance at the therapeutic potential of irisin against diseases involving inflammation, oxidative stress, and apoptosis: an introductory review. Pharm. Res., 2018, 129: 44-55.

[31] Park MJ, Kim DI, Choi JH, Heo YR, Park SH. New role of irisin in hepatocytes: the protective effect of hepatic steatosis in vitro. Cell Signal, 2015, 27: 1831-1839.

[32] Xiong XQ, et al.. FNDC5 overexpression and irisin ameliorate glucose/lipid metabolic derangements and enhance lipolysis in obesity. Biochim. Biophys. Acta, 2015, 1852: 1867-1875.

[33] Liu TY, et al.. FNDC5 alleviates hepatosteatosis by restoring AMPK/mTOR-mediated autophagy, fatty acid oxidation, and lipogenesis in mice. Diabetes, 2016, 65: 3262-3275.

[34] Zhu W, et al.. Exercise-Induced Irisin Decreases Inflammation and Improves NAFLD by Competitive Binding with MD2. Cells, 2021, 10: 3306.

[35] Armandi A, et al.. Crosstalk between irisin levels, liver fibrogenesis and liver damage in non-obese, non-diabetic individuals with non-alcoholic fatty liver disease. J. Clin. Med., 2022, 11: 635.

[36] Bonewald LF. The amazing osteocyte. J. Bone Miner. Res., 2011, 26: 229-238.

[37] Dallas SL, Prideaux M, Bonewald LF. The osteocyte: an endocrine cell … and more. Endocr. Rev., 2013, 34: 658-690.

[38] Rosenberg N, Rosenberg O, Soudry M. Osteoblasts in bone physiology-mini review. Rambam Maimonides Med. J., 2012, 3. ArticleID: e0013

[39] Feng X, Teitelbaum SL. Osteoclasts: new insights. Bone Res., 2013, 1: 11-26.

[40] Klein-Nulend J, et al.. Sensitivity of osteocytes to biomechanical stress in vitro. FASEB J., 1995, 9: 441-445.

[41] Bonewald LF, Johnson ML. Osteocytes, mechanosensing and Wnt signaling. Bone, 2008, 42: 606-615.

[42] Huang J, et al.. Fibroblast growth factor 9 (FGF9) inhibits myogenic differentiation of C2C12 and human muscle cells. Cell Cycle, 2019, 18: 3562-3580.

[43] Lara-Castillo N, Johnson ML. Bone-muscle mutual interactions. Curr. Osteoporos. Rep., 2020, 18: 408-421.

[44] Xiong J, et al.. Matrix-embedded cells control osteoclast formation. Nat. Med, 2011, 17: 1235-1241.

[45] Bonewald L. Use it or lose it to age: a review of bone and muscle communication. Bone, 2019, 120: 212-218.

[46] Brotto M, Bonewald L. Bone and muscle: interactions beyond mechanical. Bone, 2015, 80: 109-114.

[47] Kitase Y, et al.. β-aminoisobutyric acid, l-BAIBA, is a muscle-derived osteocyte survival factor. Cell Rep., 2018, 22: 1531-1544.

[48] Shimonty A, Bonewald LF, Pin F. Role of the osteocyte in musculoskeletal disease. Curr. Osteoporos. Rep., 2023, 21: 303-310.

[49] Kirk B, Feehan J, Lombardi G, Duque G. Muscle, bone, and fat crosstalk: the biological role of myokines, osteokines, and adipokines. Curr. Osteoporos. Rep., 2020, 18: 388-400.

[50] Gonzalez-Gil, A. M. & Elizondo-Montemayor, L. The role of exercise in the interplay between myokines, hepatokines, osteokines, adipokines, and modulation of inflammation for energy substrate redistribution and fat mass loss: a review. Nutrients12, 1899 (2020).

[51] Welc SS, Brotto M, White KE, Bonewald LF. Aging: a struggle for beneficial to overcome negative factors made by muscle and bone. Mech. Ageing Dev., 2025, 224. ArticleID: 112039

[52] Luo Y, et al.. Disordered metabolism in mice lacking irisin. Sci. Rep., 2020, 10. ArticleID: 17368

[53] Estell, E. G. et al. Irisin directly stimulates osteoclastogenesis and bone resorption in vitro and in vivo. Elife9, e58172 (2020).

[54] Zhu X, et al.. Irisin deficiency disturbs bone metabolism. J. Cell Physiol., 2021, 236: 664-676.

[55] Chen J, et al.. Osx-Cre targets multiple cell types besides osteoblast lineage in postnatal mice. PLoS One, 2014, 9: e85161.

[56] Couasnay G, Madel MB, Lim J, Lee B, Elefteriou F. Sites of Cre-recombinase activity in mouse lines targeting skeletal cells. J. Bone Miner. Res., 2021, 36: 1661-1679.

[57] Dallas SL, Xie Y, Shiflett LA, Ueki Y. Mouse Cre models for the study of bone diseases. Curr. Osteoporos. Rep., 2018, 16: 466-477.

[58] Colaianni G, et al.. Irisin enhances osteoblast differentiation in vitro. Int. J. Endocrinol., 2014, 2014. ArticleID: 902186

[59] Colucci S, et al.. Irisin prevents microgravity-induced impairment of osteoblast differentiation in vitro during the space flight CRS-14 mission. FASEB J., 2020, 34: 10096-10106.

[60] Qiao X, et al.. Corrigendum: Irisin promotes osteoblast proliferation and differentiation via activating the MAP kinase signaling pathways. Sci. Rep., 2016, 6. ArticleID: 21053

[61] Zhang J, et al.. Exercise-induced irisin in bone and systemic irisin administration reveal new regulatory mechanisms of bone metabolism. Bone Res., 2017, 5. ArticleID: 16056

[62] Zhang D, et al.. The bone anabolic effects of irisin are through preferential stimulation of aerobic glycolysis. Bone, 2018, 114: 150-160.

[63] Chen X, et al.. Irisin promotes osteogenic differentiation of bone marrow mesenchymal stem cells by activating autophagy via the Wnt//β-catenin signal pathway. Cytokine, 2020, 136. ArticleID: 155292

[64] Ye W, Wang J, Lin D, Ding Z. The immunomodulatory role of irisin on osteogenesis via AMPK-mediated macrophage polarization. Int. J. Biol. Macromol., 2020, 146: 25-35.

[65] Colaianni G, et al.. The myokine irisin increases cortical bone mass. Proc. Natl. Acad. Sci. USA, 2015, 112: 12157-12162.

[66] Colucci SC, et al.. Systemic administration of recombinant irisin accelerates fracture healing in mice. Int. J. Mol. Sci., 2021, 22: 10863.

[67] Ohyama Y, et al.. Effect of recombinant irisin on recombinant human bone morphogenetic protein-2 induced osteogenesis and osteoblast differentiation. Biochem. Biophys. Res. Commun., 2024, 734. ArticleID: 150787

[68] Tao L, et al.. Exerkine FNDC5/irisin-enriched exosomes promote proliferation and inhibit ferroptosis of osteoblasts through interaction with Caveolin-1. Aging Cell, 2024, 23. ArticleID: e14181

[69] Wu M, et al.. Aerobic exercise prevents renal osteodystrophy via irisin-activated osteoblasts. JCI Insight, 2025, 10: e184468.

[70] Xing S, et al.. Irisin reshapes bone metabolic homeostasis to delay age-related osteoporosis by regulating the multipotent differentiation of BMSCs via Wnt pathway. Front. Mol. Biosci., 2024, 11. ArticleID: 1524978

[71] Hatakeyama J, Inoue S, Jiang H, Yokoi R, Moriyama H. Exercise-induced interactions between skeletal muscle and bone via myokines and osteokine in mice: role of FNDC5/irisin, IGF-1, and osteocalcin. Bone, 2025, 190. ArticleID: 117314

[72] Açan AE, et al.. Irisin and its role in fracture healing: a comparative study with hyaluronic acid and platelet-rich plasma in a rat model. Jt. Dis. Relat. Surg., 2025, 36: 328-339.

[73] Wang Y, et al.. Irisin mitigates osteoporotic-associated bone loss and gut dysbiosis in ovariectomized mice by modulating microbiota, metabolites, and intestinal barrier integrity. BMC Musculoskelet. Disord., 2025, 26. ArticleID: 374

[74] Estell, E. et al. Irisin enhances mitochondrial function in osteoclast progenitors during differentiation. Biomedicines11, 3311 (2023).

[75] Ma, Y. et al. Irisin promotes proliferation but inhibits differentiation in osteoclast precursor cells. FASEB J.32, 5813–5823 (2018).

[76] Zhao C, Wang Y, Cao Z, Zhu J, He H. Effect of irisin on the expression of osteoclast-related genes in cementoblasts. Eur. J. Orthod., 2022, 44: 420-426.

[77] Kawao N, Moritake A, Tatsumi K, Kaji H. Roles of irisin in the linkage from muscle to bone during mechanical unloading in mice. Calcif. Tissue Int., 2018, 103: 24-34.

[78] Colaianni G, et al.. Irisin prevents and restores bone loss and muscle atrophy in hind-limb suspended mice. Sci. Rep., 2017, 7. ArticleID: 2811

[79] Luo Y, et al.. Irisin ameliorates bone loss in ovariectomized mice. Climacteric, 2020, 23: 496-504.

[80] Morgan EN, Alsharidah AS, Mousa AM, Edrees HM. Irisin has a protective role against osteoporosis in ovariectomized rats. Biomed. Res. Int., 2021, 2021. ArticleID: 5570229

[81] Teti A, Zallone A. Do osteocytes contribute to bone mineral homeostasis? Osteocytic osteolysis revisited. Bone, 2009, 44: 11-16.

[82] Feng JQ, Ye L, Schiavi S. Do osteocytes contribute to phosphate homeostasis?. Curr. Opin. Nephrol. Hypertens., 2009, 18: 285-291.

[83] Robling AG, Bonewald LF. The osteocyte: new insights. Annu. Rev. Physiol., 2020, 82: 485-506.

[84] Mo C, Romero-Suarez S, Bonewald L, Johnson M, Brotto M. Prostaglandin E2: from clinical applications to its potential role in bone- muscle crosstalk and myogenic differentiation. Recent Pat. Biotechnol., 2012, 6: 223-229.

[85] Xiong J, O’Brien CA. Osteocyte RANKL: new insights into the control of bone remodeling. J. Bone Miner. Res., 2012, 27: 499-505.

[86] Ono T, Hayashi M, Sasaki F, Nakashima T. RANKL biology: bone metabolism, the immune system, and beyond. Inflamm. Regen., 2020, 40: 2.

[87] Marcadet L, Bouredji Z, Argaw A, Frenette J. The roles of RANK/RANKL/OPG in cardiac, skeletal, and smooth muscles in health and disease. Front. Cell Dev. Biol., 2022, 10. ArticleID: 903657

[88] Kim JA, et al.. Association of serum sclerostin levels with low skeletal muscle mass: the Korean Sarcopenic Obesity Study (KSOS). Bone, 2019, 128. ArticleID: 115053

[89] Pin F, Bonewald LF, Bonetto A. Role of myokines and osteokines in cancer cachexia. Exp. Biol. Med., 2021, 246: 2118-2127.

[90] Robling AG, et al.. Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J. Biol. Chem., 2008, 283: 5866-5875.

[91] Huang J, et al.. Crosstalk between MLO-Y4 osteocytes and C2C12 muscle cells is mediated by the Wnt/β-catenin pathway. JBMR, 2017, 1: 86-100

[92] Bonnet N, Bourgoin L, Biver E, Douni E, Ferrari S. RANKL inhibition improves muscle strength and insulin sensitivity and restores bone mass. J. Clin. Investig., 2019, 129: 3214-3223.

[93] Pin F, et al.. RANKL blockade reduces cachexia and bone loss induced by non-metastatic ovarian cancer in mice. J. Bone Miner. Res., 2022, 37: 381-396.

[94] Tsourdi E, Jähn K, Rauner M, Busse B, Bonewald LF. Physiological and pathological osteocytic osteolysis. J. Musculoskelet. Neuronal Interact., 2018, 18: 292-303

[95] Qing H, et al.. Demonstration of osteocytic perilacunar/canalicular remodeling in mice during lactation. J. Bone Miner. Res., 2012, 27: 1018-1029.

[96] Wysolmerski JJ. Osteocytes remove and replace perilacunar mineral during reproductive cycles. Bone, 2013, 54: 230-236.

[97] Jähn K, et al.. Osteocytes acidify their microenvironment in response to PTHrP in vitro and in lactating mice in vivo. J. Bone Miner. Res., 2017, 32: 1761-1772.

[98] Qing H, Bonewald LF. Osteocyte remodeling of the perilacunar and pericanalicular matrix. Int. J. Oral. Sci., 2009, 1: 59-65.

[99] Storlino G, et al.. Irisin prevents disuse-induced osteocyte apoptosis. J. Bone Miner. Res, 2020, 35: 766-775.

[100] He Z, et al.. Irisin inhibits osteocyte apoptosis by activating the Erk signaling pathway in vitro and attenuates ALCT-induced osteoarthritis in mice. Bone, 2020, 141. ArticleID: 115573

[101] Li H, et al.. Irisin reduces senile osteoporosis by inducing osteocyte mitophagy through AMPK activation. iScience, 2024, 27. ArticleID: 111042

[102] Shimonty, A. et al. Irisin modulates murine osteocytic osteolysis in a sex and age-specific manner. JBMR38, 339–339 (2023).

[103] Prideaux M, et al.. L-BAIBA synergizes with sub-optimal mechanical loading to promote new bone formation. JBMR, 2023, 7: e10746

[104] Barros-Aragão FGQ, Januszkiewicz E, Hunter T, Lyra ESNM, De Felice FG. Physical activity in Alzheimer’s disease prevention: sex differences and the roles of BDNF and irisin. Front. Neuroendocrinol., 2025, 77. ArticleID: 101189

[105] Dicarlo M, et al.. Irisin levels in cerebrospinal fluid correlate with biomarkers and clinical dementia scores in Alzheimer disease. Ann. Neurol., 2024, 96: 61-73.

[106] Guo Y, et al.. Physical function is associated with cognitive status, brain amyloid-beta deposition, and blood biomarkers in Chinese Han population. CNS Neurosci. Ther., 2024, 30. ArticleID: e14921

[107] Bretland KA, et al.. Irisin treatment lowers levels of phosphorylated tau in the hippocampus of pre-symptomatic female but not male htau mice. Neuropathol. Appl Neurobiol., 2021, 47: 967-978.

[108] Brondani LA, et al.. Irisin-encoding gene (FNDC5) variant is associated with changes in blood pressure and lipid profile in type 2 diabetic women but not in men. Metabolism, 2015, 64: 952-957.

[109] Lai E, Sands J, Unniappan S. Fibronectin type III domain-containing protein 5 (FNDC5)-like immunoreactivity and mRNA abundance in domestic animal tissues. Vet. J., 2024, 306. ArticleID: 106161

[110] Li X, Fang W, Hu Y, Wang Y, Li J. Characterization of fibronectin type III domain-containing protein 5 (FNDC5) gene in chickens: Cloning, tissue expression, and regulation of its expression in the muscle by fasting and cold exposure. Gene, 2015, 570: 221-229.

[111] Fain JN, et al.. Exercise training does not increase muscle FNDC5 protein or mRNA expression in pigs. Metabolism, 2013, 62: 1503-1511.

[112] Basini, G. et al. Effects of the myokine irisin on stromal cells from swine adipose tissue. Biomolecules12, 1895 (2022).

[113] Hei, W. et al. FNDC5 promotes adipogenic differentiation of primary preadipocytes in mashen pigs. Genes14, 90 (2022).

[114] Dong Y, et al.. Fibronectin type III domain-containing protein 5 promotes proliferation and differentiation of goat adipose-derived stem cells. Res. Vet. Sci., 2019, 125: 351-359.

[115] Kerschan-Schindl, K. et al. Assessment of bone microstructure by Micro CT in C57BL/6J mice for sex-specific differentiation. Int. J.Mol. Sci.23, 14585 (2022).

[116] Alswat KA. Gender disparities in osteoporosis. J. Clin. Med. Res., 2017, 9: 382-387.

[117] Glatt V, Canalis E, Stadmeyer L, Bouxsein ML. Age-related changes in trabecular architecture differ in female and male C57BL/6J mice. J. Bone Miner. Res., 2007, 22: 1197-1207.

[118] Gabet Y, Bab I. Microarchitectural changes in the aging skeleton. Curr. Osteoporos. Rep., 2011, 9: 177-183.

[119] Lu D, et al.. Temporal and quantitative transcriptomic differences define sexual dimorphism in murine postnatal bone aging. JBMR, 2022, 6: e10579

[120] Osipov B, et al.. Sex differences in systemic bone and muscle loss following femur fracture in mice. J. Orthop. Res., 2022, 40: 878-890.

[121] Kurapaty SS, Hsu WK. Sex-based difference in bone healing: a review of recent pre-clinical literature. Curr. Rev. Musculoskelet. Med., 2022, 15: 651-658.

[122] Sharma A, et al.. Sexing bones: improving transparency of sex reporting to address bias within preclinical studies. J. Bone Miner. Res., 2023, 38: 5-13.

[123] Youlten SE, et al.. Osteocyte transcriptome mapping identifies a molecular landscape controlling skeletal homeostasis and susceptibility to skeletal disease. Nat. Commun., 2021, 12. ArticleID: 2444

[124] Mumtaz H, et al.. Age-related and sex-specific effects on architectural properties and biomechanical response of the C57BL/6N mouse femur, tibia and ulna. Bone Rep., 2020, 12. ArticleID: 100266

[125] Kim S, Won CW. Sex-different changes of body composition in aging: a systemic review. Arch. Gerontol. Geriatr., 2022, 102. ArticleID: 104711

[126] Goltzman D. Physiology of parathyroid hormone. Endocrinol. Metab. Clin. North Am., 2018, 47: 743-758.

[127] Hasan, A. A., Hocher, C. F., Kleuser, B., Krämer, B. K. & Hocher, B. Biological activity of different forms of oxidized parathyroid hormone. Int. J. Mol. Sci.23, 12228 (2022).

[128] Dempster DW, et al.. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J. Bone Miner. Res., 2001, 16: 1846-1853.

[129] Bouxsein ML, et al.. Ovariectomy-induced bone loss varies among inbred strains of mice. J. Bone Miner. Res., 2005, 20: 1085-1092.

[130] Tsourdi, E., Anastasilakis, A. D., Hofbauer, L. C., Rauner, M. & Lademann, F. Irisin and bone in sickness and in health: a narrative review of the literature. J. Clin. Med.11, 6863 (2022).

[131] Anastasilakis AD, et al.. Circulating irisin in healthy, young individuals: day-night rhythm, effects of food intake and exercise, and associations with gender, physical activity, diet, and body composition. J. Clin. Endocrinol. Metab., 2014, 99: 3247-3255.

[132] Singhal V, et al.. Irisin levels are lower in young amenorrheic athletes compared with eumenorrheic athletes and non-athletes and are associated with bone density and strength estimates. PLoS One, 2014, 9: e100218.

[133] Soininen S, et al.. Body fat mass, lean body mass and associated biomarkers as determinants of bone mineral density in children 6-8years of age—The Physical Activity and Nutrition in Children (PANIC) study. Bone, 2018, 108: 106-114.

[134] Colaianni G, et al.. Irisin serum levels are positively correlated with bone mineral status in a population of healthy children. Pediatr. Res., 2019, 85: 484-488.

[135] Faienza MF, et al.. High irisin levels are associated with better glycemic control and bone health in children with Type 1 diabetes. Diab. Res. Clin. Pract., 2018, 141: 10-17.

[136] Sharma Ghimire, P., Eckart, A., Al-Makhzoomy, I. K. & Stavitz, J. Sex differences in bone, muscle, and inflammatory markers and their associations with muscle performance variables. Sports11, 215 (2023).

[137] Ward K, Mulder E, Frings-Meuthen P, O’Gorman DJ, Cooper D. The effect of 60 days of 6° head-down-tilt bed rest on circulating adropin, irisin, retinol binding protein-4 (RBP4) and individual metabolic responses in young, healthy males. Front. Physiol., 2024, 15. ArticleID: 1435448

[138] Gil-Cosano, J. J. et al. Movement behaviors and bone biomarkers in young pediatric cancer survivors: a cross-sectional analysis of the iBoneFIT project. Nutrients16, 3914 (2024).

[139] Campisi J, et al.. From discoveries in ageing research to therapeutics for healthy ageing. Nature, 2019, 571: 183-192.

[140] Carapeto PV, Aguayo-Mazzucato C. Effects of exercise on cellular and tissue aging. Aging, 2021, 13: 14522-14543.

[141] Zhang H, Wu X, Liang J, Kirberger M, Chen N. Irisin, an exercise-induced bioactive peptide beneficial for health promotion during aging process. Ageing Res. Rev., 2022, 80. ArticleID: 101680

[142] Colaianni G, et al.. Irisin correlates positively with BMD in a cohort of older adult patients and downregulates the senescent marker p21 in osteoblasts. J. Bone Miner. Res., 2021, 36: 305-314.

[143] Miyamoto-Mikami E, et al.. Endurance training-induced increase in circulating irisin levels is associated with reduction of abdominal visceral fat in middle-aged and older adults. PLoS One, 2015, 10: e0120354.

[144] Wu LF, et al.. Association of plasma irisin with bone mineral density in a large chinese population using an extreme sampling design. Calcif. Tissue Int., 2018, 103: 246-251.

[145] Zhang J, Huang X, Yu R, Wang Y, Gao C. Circulating irisin is linked to bone mineral density in geriatric Chinese men. Open Med., 2020, 15: 763-768.

[146] Zhou K, Qiao X, Cai Y, Li A, Shan D. Lower circulating irisin in middle-aged and older adults with osteoporosis: a systematic review and meta-analysis. Menopause, 2019, 26: 1302-1310.

[147] Palermo A, et al.. Irisin is associated with osteoporotic fractures independently of bone mineral density, body composition or daily physical activity. Clin. Endocrinol., 2015, 82: 615-619.

[148] Albrecht E, et al.. Irisin: still chasing shadows. Mol. Metab., 2020, 34: 124-135.

[149] Albrecht E, et al.. Irisin—a myth rather than an exercise-inducible myokine. Sci. Rep., 2015, 5. ArticleID: 8889

[150] Jedrychowski MP, et al.. Detection and quantitation of circulating human irisin by tandem mass spectrometry. Cell Metab., 2015, 22: 734-740.

[151] Iemura S, Kawao N, Okumoto K, Akagi M, Kaji H. Role of irisin in androgen-deficient muscle wasting and osteopenia in mice. J. Bone Miner. Metab., 2020, 38: 161-171.

[152] Colaianni G, et al.. Irisin levels correlate with bone mineral density in soccer players. J. Biol. Regul. Homeost. Agents, 2017, 31: 21-28

[153] Notaristefano G, et al.. Circulating irisin levels in functional hypothalamic amenorrhea: a new bone damage index? A pilot study. Endocrine, 2022, 77: 168-176.

[154] Barp A, et al.. Body composition and myokines in a cohort of patients with Becker muscular dystrophy. Muscle Nerve, 2022, 66: 63-70.

[155] Wang X, et al.. The association of serum irisin with bone mineral density and turnover markers in new-onset type 2 diabetic patients. Int. J. Endocrinol., 2022, 2022. ArticleID: 7808393

[156] Anastasilakis AD, et al.. Circulating irisin is associated with osteoporotic fractures in postmenopausal women with low bone mass but is not affected by either teriparatide or denosumab treatment for 3 months. Osteoporos. Int., 2014, 25: 1633-1642.

Funding

National Institute of Health National Institute of Aging United States

RIGHTS & PERMISSIONS

The Author(s)